Genomed SA
WSE:GEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genomed SA
Operating Income
Genomed SA
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genomed SA
WSE:GEN
|
Operating Income
zł4.3m
|
CAGR 3-Years
130%
|
CAGR 5-Years
56%
|
CAGR 10-Years
72%
|
|
|
M
|
Mabion SA
WSE:MAB
|
Operating Income
-zł56.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
0%
|
CAGR 10-Years
-26%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Operating Income
zł1m
|
CAGR 3-Years
54%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bioton SA
WSE:BIO
|
Operating Income
zł13.9m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
2%
|
|
|
U
|
Urteste SA
WSE:URT
|
Operating Income
-zł4.2m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Operating Income
-zł2.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-15%
|
|
Genomed SA
Glance View
Genomed SA engages in the provision of medical diagnostic services. The company is headquartered in Warsaw, Woj. Mazowieckie. The company went IPO on 2011-05-30. The company develops molecular diagnostics based on deoxyribonucleic acid (DNA) sequencing, with a special focus on the Next Generation Sequencing (NGS) method. The Company’s offer includes the analysis of gene mutations responsible for over 150 congenital diseases, such as infertility, predisposition to cancer, cystic fibrosis (CF), Alzheimer's disease, hearing loss, coeliac disease, cardiomyopathy and obesity, among others. The Company’s activities are directed toward introducing genomic technology to personalized medicine and creating a clinic offering gene treatments. The firm also provides diverse DNA sequencing, analysis and synthesis services for research and the biotechnological market.
See Also
What is Genomed SA's Operating Income?
Operating Income
4.3m
PLN
Based on the financial report for Dec 31, 2025, Genomed SA's Operating Income amounts to 4.3m PLN.
What is Genomed SA's Operating Income growth rate?
Operating Income CAGR 10Y
72%
Over the last year, the Operating Income growth was 259%. The average annual Operating Income growth rates for Genomed SA have been 130% over the past three years , 56% over the past five years , and 72% over the past ten years .
